2024-03-29T06:59:22Zhttps://www.tdx.cat/oai/requestoai:www.tdx.cat:10803/16142017-08-30T21:10:36Zcom_10803_1col_10803_54
TDX (Tesis Doctorals en Xarxa)
author
Pujals Naranjo, Georgina
authoremail
georginapujals@ub.edu
authoremailshow
true
director
Carrió Díaz-Meco, Jaume
director
Miñarro Carmona, Montserrat
director
Ticó Grau, Josep Ramon
2011-04-12T13:37:22Z
2008-01-09
2007-12-14
9788469112960
http://www.tdx.cat/TDX-0109108-121141http://hdl.handle.net/10803/1614
B.13341-2008
The aim of this work is to develop an effective new MGA delivery system by means of nanotechnology for the treatment of leishmaniosis which could be administered by parenteral or oral route in a future. Moreover, for ensuring the effectiveness of the formulations developed, their in vitro activities will be assessed against L. infantum. The intention is to prepare a target drug delivery system by means of different technological strategies like micro-nanoparticles by spray drying. These formulations should target the antileishmanial drug to the macrophages which are the host cells of Leishmania parasites. If this purpose was achieved the drug bioavaibility would be increased, therefore lower doses could be administered, reducing the side effects and improving the efficiency of the treatment. <br/>The main objective can be summarized as to develop and characterize a new MGA formulation using nanotechnologies. It implies: <br/>1. To study in vitro the effectiveness and cytotoxicity of formulations against Leishmania. <br/>2. To develop preliminary in vitro uptake studies in macrophages using quantum dots assisted imaging.<br/>3. To study MGA release profile from the new delivery device developed.<br/><br/>The present development of a new dosage form of MGA starts with the elaboration of emulsions, self-emulsifying drug delivery systems and nanosuspensions. However, the main part is centralized by the microencapsulation of MGA by spray drying using the preliminary studies as reference and the polymer chitosan as the main excipient. Spray drying technique has been used to elaborate two kinds of nano/microspheres, on one side those which come from emulsions and on the other side those which come from solutions. Both cases have been morphologically characterized and their effectiveness has been studied in vitro against Leishmania parasites. Moreover, the ability to be phagocyted by macrophages cells has been investigated using quantum dots assisted imaging in the Department of Pharmaceutical Sciences of the University of Connecticut during a stage.<br/><br/>A new meglumine antimoniate delivery device for the treatment of leishmaniosis has been properly developed using spray drying technique achieving efficiencies of encapsulation higher than 90 % and process yields of 60 %. All the antimony IC50 values from encapsulated meglumine antimoniate in the chitosan microspheres tested against promastigotes and amastigotes are considerably lower compared to the mean value of IC50 in Glucantime® solution and give an Safety Index ratio higher than 1. Moreover, it is reported for the first time a novel in vitro activity of chitosan against L.infantum with a low cytotoxicity in macrophages assays (PATENEP P200700968). The uptake studies confirm the better suitability of chitosan as polymer to target drugs to macrophages compared to the commonly used PLGA.<br/>It has been shown that high percentages of chitosan in solutions to be spray-dried reduce the yield of the process, produce larger wrinkled microspheres but increase the efficiency of encapsulation. Chitosan microspheres exhibit a biphasic prolonged release for 24 h, characterized by an initial burst effect followed by slow release. High polymer ratios reduce the drug release in all the study. Moreover, high percentages of glutaraldehid in chitosan microspheres tend to increase significantly the presence of Non-Fickian drug release mechanism. These microspheres show the slowest release for the first 3 h but the highest percentage of drug released at 24 h. Moreover, they are among the more active microspheres against L.infantum. The minimum antimony IC50 value of chitosan microspheres is obtained using high percentages of glutaraldehid, low percentages of chitosan and low inlet temperatures. This new delivery system could offer a new pharmacological tool for treatment of leishmaniosis that reduces the doses required, lowering toxic side effects due to meglumine antimoniate.
eng
Quitosà
Leishmania
Microencapsulació
Nanosuspensions
Emulsions
Nanotecnologia
Antomoniat de meglumina (AMG)
Targeting of antileishmanial drugs produced by nanotechnologies
info:eu-repo/semantics/doctoralThesis info:eu-repo/semantics/publishedVersion
URL
https://www.tdx.cat/bitstream/10803/1614/1/00.GPN_PREVIOUS.pdf
File
MD5
46ec2c94a4ab0c67fff3b35528573072
92944
application/pdf
00.GPN_PREVIOUS.pdf
URL
https://www.tdx.cat/bitstream/10803/1614/2/01.GPN_BIBLIOGRAPHIC_SECTION.pdf
File
MD5
97325ba6015f75bd1b47016e1e0dd68b
1077042
application/pdf
01.GPN_BIBLIOGRAPHIC_SECTION.pdf
URL
https://www.tdx.cat/bitstream/10803/1614/3/02.GPN_EXPERIMENTAL_SECTION.pdf
File
MD5
c724b79749c0a3b7160e7a9ec844c947
5782765
application/pdf
02.GPN_EXPERIMENTAL_SECTION.pdf
URL
https://www.tdx.cat/bitstream/10803/1614/4/03.GPN_BIBLIOGRAPHY.pdf
File
MD5
064f0239eef079959d3d5c62d1c36808
109601
application/pdf
03.GPN_BIBLIOGRAPHY.pdf
URL
https://www.tdx.cat/bitstream/10803/1614/5/04.GPN_ANNEX_CATALA.pdf
File
MD5
cf8a07532b6c6f24124a16784d26a07a
234677
application/pdf
04.GPN_ANNEX_CATALA.pdf
URL
https://www.tdx.cat/bitstream/10803/1614/6/04.GPN_ANNEX_CATALA.pdf.txt
File
MD5
449d8ef6ea464ac818ce475d54467a61
121644
text/plain
04.GPN_ANNEX_CATALA.pdf.txt
URL
https://www.tdx.cat/bitstream/10803/1614/7/03.GPN_BIBLIOGRAPHY.pdf.txt
File
MD5
a4615122304eae813d8439c40e850a3b
50528
text/plain
03.GPN_BIBLIOGRAPHY.pdf.txt
URL
https://www.tdx.cat/bitstream/10803/1614/8/02.GPN_EXPERIMENTAL_SECTION.pdf.txt
File
MD5
81fc8e7181e64ad30a150dd00a31732e
233254
text/plain
02.GPN_EXPERIMENTAL_SECTION.pdf.txt
URL
https://www.tdx.cat/bitstream/10803/1614/9/01.GPN_BIBLIOGRAPHIC_SECTION.pdf.txt
File
MD5
bb07a9c6faa88cc914451222a0e6b7b2
90155
text/plain
01.GPN_BIBLIOGRAPHIC_SECTION.pdf.txt
URL
https://www.tdx.cat/bitstream/10803/1614/10/00.GPN_PREVIOUS.pdf.txt
File
MD5
47b6e0c65550f60777616d5b428b1eae
25541
text/plain
00.GPN_PREVIOUS.pdf.txt